LivaNova (LIVN) Financials, Dividends & Stock Info
Explore comprehensive financial data for LivaNova, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (571 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
LivaNova (LIVN) is a health care equipment company. The company reports annual revenue of $1.3B and net loss of $217M. Its profit margin is -16.1%.
LivaNova Key Financials(TTM Est.)
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
LivaNova Financial Health ScoreFY2025
Moderate health; several metrics need attention
-10 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Altman Z-Score 0.84 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
About LivaNova
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
- Industry
- Health Care Equipment
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Thin Marginsvs 9.0% sector median / 11.9% avg
Currently generating negative returns on shareholder equity.
vs 7.9% sector median / 7.6% avg
Currently operating at a loss of 16 cents per dollar of revenue.
3rd consecutive year of revenue growth.
* Some quarterly data is missing. Values are calculated based on annual report figures.
Profit margin 313% below sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Low Leveragevs 0.59 sector median / 0.57 avg
Carries $0.38 in debt for every $1 of equity. Lower debt than 78% in Health Care. Debt has increased over the past 5 years.
Debt-to-equity ratio of 0.38 is below 0.5.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
LivaNova 10-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B(+10.7%) | $1.3B(+8.7%) | $1.2B(+23.5%) | $934.2M(-13.8%) | $1.1B(+16.0%) | $934.2M(-13.8%) | $1.1B(-2.1%) | $1.1B(+9.4%) | $1.0B(+4.9%) | $964.9M(+165.6%) |
| Net Income | $-242,471,000(-483.5%) | $63.2M(+260.4%) | $17.5M(+105.0%) | $-348,819,000(-121.3%) | $-157,639,000(+54.8%) | $-348,819,000(-121.3%) | $-157,639,000(+16.8%) | $-189,399,000(-654.9%) | $-25,089,000(+60.0%) | $-62,789,000(-112.0%) |
| Total Assets | $2.6B | $2.5B | $2.4B | $2.3B | $2.2B | $2.4B | $2.4B | $2.5B | $2.5B | $2.3B |
| Total Debt | $376.1M | $627.0M | $586.0M | $539.0M | $236.8M | $650.7M | $333.5M | $139.5M | $62.0M | $122.9M |
| Total Equity | $1.2B | $1.3B | $1.3B | $1.1B | $1.4B | $1.1B | $1.4B | $1.5B | $1.8B | $1.7B |
| Profit Margin | -17.5% | 5.0% | 1.5% | -37.3% | -14.5% | -37.3% | -14.5% | -17.1% | -2.5% | -6.5% |
| ROE | -20.2% | 4.8% | 1.4% | -31.4% | -11.4% | -31.4% | -11.4% | -12.6% | -1.4% | -3.7% |
| ROA | -9.3% | 2.5% | 0.7% | -15.2% | -7.2% | -14.5% | -6.5% | -7.4% | -1.0% | -2.7% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $316.9M | $357.8M | $352.5M | $316.9M | $318.1M | $318.6M | $294.9M | $286.1M |
| Net Income | $-327,322,000 | $26.8M | $27.2M | $-327,322,000 | $33.0M | $16.3M | $-41,943,000 | $-7,318,000 |
| Total Assets | $2.6B | $2.6B | $2.5B | $2.6B | $2.5B | $2.5B | $2.5B | $2.3B |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
LivaNova Free Cash Flow & Dividend Coverage
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | $90.2M | $91.3M | $120.5M | -$91.1M | -$79.4M | -$91.1M | -$79.4M | $74.9M | $183.0M | $254.3M |
| CapEx | -$38.4M | -$32.9M | -$37.2M | -$24.7M | -$35.0M | -$24.7M | -$35.0M | -$35.0M | -$47.1M | -$81.0M |
| Free Cash Flow | $51.8M | $58.4M | $83.3M | -$115.8M | -$114.4M | -$115.8M | -$114.4M | $39.9M | $135.9M | $173.3M |
| FCF Margin | 5.4% | 5.8% | 7.5% | -10.7% | -12.3% | -10.7% | -12.3% | 3.5% | 10.8% | 12.5% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
LivaNova Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for LIVN.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
LivaNova FAQ
What is LivaNova's annual revenue?
LivaNova (LIVN) reported $1.3 billion in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is LivaNova profitable?
LivaNova reported a net loss with a -16.1% profit margin, totaling $217 million in net losses (TTM). All figures from SEC EDGAR 10-K filings.
Does LivaNova pay dividends?
No, LivaNova (LIVN) does not currently pay dividends to shareholders.
What is LivaNova's financial health score?
LivaNova has a financial health score of 60/100 (Grade: C), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of LivaNova financial data are available?
10 years of financial data are available for LivaNova from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.